FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| OMB APPROVAL             |           |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person *  |  |                          |   |                                 | 2. Issuer Name and Ticker or Trading Symbol                 |   |   |                                   |                                    |  |   |  | 5. Relationship of Reporting Person(s) to Issuer  |   |               |   |                                       |  |
|--|--|--------------------------|---|---------------------------------|---|---|---|-----------------------------------|------------------------------------|--|---|--|---|---|---------------|---|---------------------------------------|--|
| Bergmann Anthony   |  |                          |   | <u></u>                         | CAPRICOR THERAPEUTICS, INC. [ CAPR ]                        |   |   |                                   |                                    |  |   | (Crieck  | (Check all applicable) Director 10% Owner   |   |               |   |                                       |  |
|  |  |                          |   |                                 | 3. Date of Earliest Transaction (Month/Day/Year) 02/12/2020 |   |   |                                   |                                    |  |   | X  | X Officer (give title Other (sp   |   |               | pecify  |                                       |  |
| (Last) (First) (Middle) C/O CAPRICOR THERAPEUTICS, INC.                          |  |                          |   |                                 | 02/12/2020  |   |   |                                   |                                    |  |   |  | ,   | below) below) CHIEF FINANCIAL OFFICER                             |               |   |                                       |  |
| 8840 WILSHIRE BLVD., 2ND FLOOR   |  |                          |   | -                               |   |   |   |                                   |                                    |  |   |  |   |   |               |   |                                       |  |
| WIESTING BEVD., 2ND LEOOK  |  |                          |   | 4                               | If Amendment, Date of Original Filed (Month/Day/Year)       |   |   |                                   |                                    |  |   |  | Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person |   |               |   |                                       |  |
| (Street)   |  |                          |   |                                 |   |   |   |                                   |                                    |  |   | "  | Form filed by More than One Reporting Person  |   |               |   |                                       |  |
| BEVERLY HILLS CA 90211   |  |                          |   |                                 |   |   |   |                                   |                                    |  |   |  |   |   |               |   |                                       |  |
| (City) (State) (Zip)   |  |                          |   |                                 |   |   |   |                                   |                                    |  |   |  |   |   |               |   |                                       |  |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |  |                          |   |                                 |   |   |   |                                   |                                    |  |   |  |   |   |               |   |                                       |  |
| Date   |  |                          |   | 2. Transac<br>Date<br>(Month/Da |   | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |   | Transaction Disposed Code (Instr. |                                    | ties Acquired (A) or<br>d Of (D) (Instr. 3, 4 and 5) |   | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported |   | 6. Ownership<br>Form: Direct (D)<br>or Indirect (I)<br>(Instr. 4) |               | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership |                                       |  |
|  |  |                          |   |                                 |   |   | Code  | v                                 | Amount                             | (A) or (D) Price                                     |   | Transaction(s) (Instr. 3 and 4)  |   |   |               | (Instr. 4)  |                                       |  |
|  |  |                          |   |                                 |   |   | •   | -                                 | •                                  |  | r Beneficia<br>e securities                               | -  | ed  |   |               |   |                                       |  |
| 1. Title of<br>Derivative  | 2.<br>Conversion                         | 3. Transaction           | 3A. Deemed                                    | 4.                              | 5. Number of  |   |   | 6. Date E                         |                                    |  | 7. Title and An   |  | 8. Price of   | 9. Numbe  |               | 10.<br>Ownership                                    | 11. Nature of Indirect                |  |
| Security (Instr.<br>3)   | or Exercise Price of Derivative Security | Date<br>(Month/Day/Year) | Execution Date,<br>if any<br>(Month/Day/Year) | Code                            | Transaction<br>Code (Instr.<br>8)                           |   | Derivative<br>Securities<br>Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4 and 5) |                                   | Expiration Date<br>(Month/Day/Year |  | Securities Under<br>Derivative Securi<br>(Instr. 3 and 4) |  |   |   | s<br>Ily<br>J | Form: Direct (D) or Indirect (I) (Instr. 4)         | Beneficial<br>Ownership<br>(Instr. 4) |  |
|  |  |                          |   |                                 | $\Box$  |   |   |                                   |                                    |  |   | Amount   | Reported<br>Transact  |   |               |   |                                       |  |
|  |  |                          |   | Code                            | v   | (A)   | (D)   | Date<br>Exercisal                 |                                    | Expiration<br>Date                                   | Title   | or<br>Number<br>of Shares  |   | (Instr. 4)  |               |   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$1.39                                   | 02/12/2020               |   | A                               |   | 14,000  |   | (1)                               |                                    | 08/08/2029   | Common<br>Stock   | 14,000   | (2)   | 14,000  |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$1.39                                   | 02/12/2020               |   | A                               |   | 5,000   |   | (3)                               |                                    | 01/02/2028   | Common<br>Stock   | 5,000  | (2)   | 5,000   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$1.39                                   | 02/12/2020               |   | A                               |   | 3,500   |   | (4)                               |                                    | 01/03/2027   | Common<br>Stock   | 3,500  | (2)   | 3,500   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$1.39                                   | 02/12/2020               |   | A                               |   | 3,000   |   | (5)                               |                                    | 06/02/2026   | Common<br>Stock   | 3,000  | (2)   | 3,000   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$1.39                                   | 02/12/2020               |   | A                               |   | 2,500   |   | (6)                               |                                    | 03/03/2025   | Common<br>Stock   | 2,500  | (2)   | 2,500   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$1.39                                   | 02/12/2020               |   | A                               |   | 2,178   |   | (6)                               |                                    | 10/23/2023   | Common<br>Stock   | 2,178  | (2)   | 2,178   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$3.25                                   | 02/12/2020               |   | D                               |   |   | 14,000  | (1)                               |                                    | 08/08/2029   | Common<br>Stock   | 14,000   | (2)   | 0   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$15.7                                   | 02/12/2020               |   | D                               |   |   | 5,000   | (3)                               |                                    | 01/02/2028   | Common<br>Stock   | 5,000  | (2)   | 0   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$25.5                                   | 02/12/2020               |   | D                               |   |   | 3,500   | (4)                               |                                    | 01/03/2027   | Common<br>Stock   | 3,500  | (2)   | 0   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$31.2                                   | 02/12/2020               |   | D                               |   |   | 3,000   | (5)                               |                                    | 06/02/2026   | Common<br>Stock   | 3,000  | (2)   | 0   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$57.8                                   | 02/12/2020               |   | D                               |   |   | 2,500   | (6)                               |                                    | 03/03/2025   | Common<br>Stock   | 2,500  | (2)   | 0   |               | D   |                                       |  |
| Stock Option<br>(Right to Buy)   | \$3                                      | 02/12/2020               |   | D                               |   |   | 2,178   | (6)                               |                                    | 10/23/2023   | Common<br>Stock   | 2,178  | (2)   | 0   |               | D   |                                       |  |

## **Explanation of Responses**

- 1. 4,666 of the shares were vested on the date of grant. The remaining 9,334 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
- 2. The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of \$1.39 per share.
- 3. The shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
- 4. The shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
- 5. The shares will vest 1/48th on the first day of each month, commencing July 1, 2016, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
- 6. The stock option award is fully vested and exercisable.

/s/ Linda Marban, as Attorney-in-

Fact

02/14/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.